Medicines in a popular new class of weight loss drugs including Ozempic and WeGovy may put patients at a higher risk for severe digestive problems, such as stomach paralysis, pancreatitis and bowel obstructions, according to a new study in JAMA Medical Journal
The drugs have shown promising clinical results, Jaisinghani and her peers emphasize
"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus." Journal of Clinical Investigation , 91(1), 301-307
Follow proper reconstitution, storage, and injection protocols
Frequently Asked Questions Is fatigue from semaglutide permanent or will it go away
However, due to the study's small sample size and lack of consistent grouping based on diagnosis or diet, the results need further investigation